FrancophonIA/ELRC3.0 huggingface dataset:
English: You will be given other medicines to reduce fever, pain or inflammation caused by Removab (see section 3).
Croatian: Primit ćete druge lijekove da bi se smanjila vrućica, bol ili upala koju je izazvao Removab (pogledajte dio 3).
English: CD3 is expressed on mature T-cells as a component of the T-cell receptor.
Croatian: CD3 je izražen na zrelim T stanicama kao sastavni dio T staničnog receptora.
English: No hypersensitivity reactions were observed.
Croatian: Nisu zabilježene reakcije preosjetljivosti.
English: HAMAs were present in 94% of patients one month after the last catumaxomab infusion.
Croatian: HAMA protutijela bila su prisutna u 94% bolesnika mjesec dana nakon posljednje infuzije katumaksomaba.
English: It recognises a protein on the surface of cancer cells and recruits immune cells to destroy them.
Croatian: Ono prepoznaje protein na površini stanica raka i potiče stanice imunološkog sustava da ih unište.
English: For information on the perfusion system to be used see section 4.4.
Croatian: Za podatke o perfuzijskom sustavu, vidjeti dio 4.4.
English: Administration of catumaxomab in animal models did not result in any signs of abnormal or drug-related acute toxicity or signs of local intolerance at the injection/infusion site.
Croatian: Primjena katumaksomaba na životinjskim modelima nije rezultirala nikakvim znakovima abnormalne ili akutne toksičnosti vezane uz lijek ili znakovima lokalne netolerancije na mjestu injekcije/infuzije.
English: • polycarbonate infusion valves / Y connections
Croatian: • polikarbonantnim infuzijskim ventilima/Y spoj
English: Hypersensitivity to murine (rat and / or mouse) proteins.
Croatian: Preosjetljivost na mišje (štakora i/ili miša) proteine.
English: • The plunger rod MUST NOT be drawn back to rinse the pre-filled syringe, in order to avoid contamination and to ensure that the correct volume is ejected.
Croatian: • Klip se NE SMIJE povlačiti prema natrag radi ispiranja napunjene štrcaljke kako bi se izbjegla kontaminacija i osiguralo da je istisnut ispravan volumen.
English: • The pump speed is adjusted according to the volume to be administered and the scheduled infusion time.
Croatian: • Brzina pumpe podešava se prema volumenu koji se mora primijeniti i rasporedu vremena infuzije.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.You should not use Removab if you are pregnant unless clearly necessary.
Croatian: Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
English: Malignant ascites is an accumulation of fluid in the abdominal space (peritoneal cavity) resulting from certain types of cancer.
Croatian: Zloćudni ascites je nakupina tekućine u trbuhu (peritonealnoj šupljini) koju uzrokuju određene vrste raka.
English: Administration of prednisolone as premedication did not result in a reduction of these adverse reactions.
Croatian: Primjena prednizolona kao premedikacije nije rezultirala smanjenjem ovih nuspojava.
English: In 43.7% of patients abdominal pain was reported as an adverse reaction reaching grade 3 in 8.2 % of patients, but it resolved under symptomatic treatment.
Croatian: U 43,7% bolesnika bol u trbuhu prijavljena je kao nuspojava stupnja 3 u 8,2% bolesnika, ali je riješena simptomatskim liječenjem.
English: An interval of at least two infusion free calendar days must elapse between infusion days.
Croatian: Razdoblje od najmanje dva kalendarska dana bez infuzije mora proći između pojedinih doza infuzije.
English: Patients experiencing infusion-related symptoms should be advised not to drive and use machines until symptoms abate.
Croatian: Bolesnike koji tijekom infuzije razviju simptome potrebno je savjetovati da ne voze i ne rade sa strojevima do povlačenja simptoma.
English: Acute infections
Croatian: Akutne infekcije
English: • An additional air buffer of at least 3 ml is included in the 50 ml syringe.
Croatian: • Dodatni jastučić zraka od najmanje 3 ml uključen je u štrcaljku od 50 ml
English: Adverse reactions are derived from an integrated safety analysis including 12 clinical studies.
Croatian: Nuspojave potječu iz integrirane sigurnosne analize koja je uključivala 12 kliničkih ispitivanja. 728
English: * were also reported as serious adverse reactions underlined: see section ‘Description of selected adverse reactions'
Croatian: * također su prijavljeni kao ozbiljne nuspojave podcrtano: vidjeti dio
English: The prepared solution for infusion is physically and chemically stable for 48 hours at 2°C to 8°C and for 24 hours at a temperature not above 25°C.
Croatian: Pripremljena otopina za infuziju fizički je i kemijski stabilna 48 sati na 2°C do 8°C i 24 sata na temperaturi ne većoj od 25°C.
English: Catumaxomab was applied in patients where standard therapy was not available or no longer feasible and who had a Karnofsky performance status of at least 60.
Croatian: Katumaksomab je primijenjen u bolesnika u kojih standardno liječenje nije bilo dostupno ili više nije bilo indicirano i koji su imali Karnofsky status najmanje 60.
English: Pooled population (N=219)
Croatian: Zajednička populacija (N=219)
English: Paracentesis (control) (N=88)
Croatian: Paracenteza (kontrola) (N=88)
English: Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC09
Croatian: Farmakoterapijska skupina: Antineoplastici, monoklonska protutijela, ATK oznaka: L01XC09 Mehanizam djelovanja
English: 1 sterile cannula
Croatian: 1 sterilna cjevčica
English: After completion of the study, patients were further observed until the end of their lifetime to assess overall survival (Table 4).
Croatian: Nakon završetka ispitivanja bolesnici su praćeni do smrti kako bi se procijenilo ukupno preživljenje (Tablica 4).
English: This must at least include ascites drainage until stop of spontaneous flow or symptom relief, and, if appropriate, supportive replacement therapy with crystalloids and / or colloids.
Croatian: Ovo mora uključivati barem evakuaciju ascitesa do zaustavljanja spontanog istjecanja ili do olakšanja simptoma i, ako je primjereno, potporno liječenje kristaloidnim i/ili koloidnim otopinama.
English: The efficacy of catumaxomab was demonstrated in two phase III clinical studies.
Croatian: Djelotvornost katumaksomaba dokazana je u dva klinička ispitivanja u fazi III.
English: In three patients (0.4%) an intensity of CTCAE grade 4 was observed.
Croatian: U tri bolesnika (0,4%) zabilježen je intenzitet stupnja 4 prema CTCAE.
English: The induction of human anti-murine (rat and / or mouse) antibodies (HAMAs/HARAs) is an intrinsic effect of murine monoclonal antibodies.
Croatian: Indukcija ljudskih protu-mišjih (štakorskih i/ili mišjih) protutijela (HAMA/HARA) intrinzični je učinak mišjih monoklonalnih protutijela.
English: A third functional binding site in the Fc-region of catumaxomab enables interaction with accessory immune cells via Fcγ receptors.
Croatian: Treće funkcionalno mjesto vezivanja u Fc regiji katumaksomaba omogućava interakciju s drugim imunološkim stanicama putem Fcγ receptora.
English: A catheter will be placed in your abdominal space (intraperitoneal) for the whole treatment period, until the day after your last infusion.
Croatian: Kateter će Vam biti u trbuhu (trbušnoj šupljini) tijekom cijelog liječenja, do dana nakon zadnje infuzije.
English: Removab should be prepared by a healthcare professional using appropriate aseptic technique.
Croatian: Removab treba pripremiti zdravstveni djelatnik prikladnom aseptičkom tehnikom.
English: These symptoms occur mainly within 24 hours after a Removab infusion and can become life-threatening, but can be treated well with additional therapy.
Croatian: Ovi se simptomi uglavnom javljaju unutar 24 sata nakon infuzije Removaba i mogu biti opasni po život, ali se uspješno rješavaju potpornim liječenjem.
English: It is recommended that the catheter remains in the abdominal cavity during the entire treatment period.
Croatian: Preporučuje se da kateter ostane u trbušnoj šupljini tijekom cijelog trajanja liječenja.
English: A complex of symptoms including very fast heartbeat, fever and shortness of breath can develop in up to 4 out of 100 patients.
Croatian: Skupina simptoma koja uključuje ubrzani rad srca, vrućicu i nedostatak zraka mogu se razviti u do 4 na 100 bolesnika.
English: If you experience side effects such as dizziness or chills during or after administration, you should not drive or use machines until they disappear.
Croatian: Ako imate nuspojave kao što su omaglica ili zimica tijekom ili nakon primjene lijeka, ne biste smjeli upravljati vozilima i strojevima dok simptomi ne nestanu.
English: Therefore, based upon the safety profile of Removab, which requires the submission of yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.
Croatian: Stoga, s obzirom na sigurnosni profil Removaba, što zahtijeva podnošenje Periodičkog izvješća o neškodljivosti lijeka (PSUR) jednom godišnje, CHMP je zaključio da Nositelj odobrenja za stavljanje gotovog lijeka u promet mora predati zahtjev za jednom dodatnom obnovom za 5 godina.
English: Removab is not recommended during pregnancy and in women of childbearing potential not using contraception.
Croatian: Ne preporučuje se koristiti lijek Removab tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
English: The overall safety profile of Removab is characterised by cytokine-release related symptoms and gastrointestinal reactions.
Croatian: Cjelokupni sigurnosni profil Removaba karakteriziraju simptomi vezani uz otpuštanje citokina i gastrointestinalne reakcije.
English: You are required to have a BMI above 17 (after drainage of the ascites fluid) and a Karnofsky Index above 60 to use this medicine.
Croatian: ITM mora biti iznad 17 (nakon evakuacije ascitesa) i Karnofsky indeks iznad 60 da biste smjeli primijeniti ovaj lijek.
English: Patients who developed HAMAs 8 days after catumaxomab treatment showed better clinical outcome, as measured by puncture-free survival, time to next puncture and overall survival, compared with HAMA-negative patients.
Croatian: Bolesnici koji su razvili HAMA protutijela 8 dana nakon liječenja katumaksomabom pokazali su bolji klinički ishod, mjereno preživljenjem bez punkcije, vremenom do sljedeće punkcije i ukupnim preživljenjem, u usporedbi s HAMA negativnim bolesnicima.
English: Other serious side effects
Croatian: Druge ozbiljne nuspojave
English: The interval between the infusion days can be prolonged in case of relevant adverse reactions.
Croatian: Interval između pojedinih doza infuzije može se produžiti u slučaju pojave značajnih nuspojava.
English: Despite this premedication, patients experienced the adverse reactions described above with an intensity of up to grade 3, according to the Common Terminology Criteria for Adverse Events (CTCAE) of the US National Cancer Institute, version 3.0.
Croatian: Unatoč navedenoj premedikaciji, bolesnici su razvili prethodno navedene nuspojave intenziteta do 3. stupnja prema Zajedničkim kriterijima terminologije za nuspojave (CTCAE) američkog Nacionalnog instituta za rak, verziji 3.0.
English: If you have any further questions on the use of this product, ask your doctor.
Croatian: U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku.
English: It is unknown whether catumaxomab/metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se katumaksomab/metaboliti u majčino mlijeko.
English: The composite safety score evaluated the frequency and severity of the main known adverse reactions pyrexia, nausea, vomiting and abdominal pain in both treatment groups.
Croatian: Kompozitni sigurnosni rezultat procjenjivao je učestalost i težinu glavnih poznatih nuspojava: pireksije, mučnine, povraćanja i boli u trbuhu u obje liječene skupine.
English: Removab has minor to moderate influence on the ability to drive and use machines.
Croatian: Removab malo do umjereno utječe na sposobnost upravljanja vozilima i rada na strojevima.
English: *rat-mouse hybrid IgG2 monoclonal antibody produced in a rat-mouse hybrid-hybridoma cell line For the full list of excipients, see section 6.1.
Croatian: *monoklonsko štakorsko-mišje hibridno IgG2 protutijelo proizvedeno u hibridoma-hibridnoj štakorsko-mišjoj staničnoj liniji Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
English: Paediatric population There is no relevant use of Removab in the paediatric population in the granted indication.
Croatian: Nema relevantne primjene Removaba u pedijatrijskoj populaciji u odobrenoj indikaciji.
English: Conditions such as hypovolaemia, hypoproteinaemia, hypotension, circulatory decompensation and acute renal impairment must be resolved prior to each Removab infusion.
Croatian: Stanja poput hipovolemije, hipoproteinemije, hipotenzije, cirkulatorne dekompenzacije i akutnog oštećenja funkcije bubrega moraju biti riješena prije svake infuzije Removaba.
English: Prior to each Removab administration the ascites fluid must be drained until stop of spontaneous flow or symptom relief (see section 4.4).
Croatian: Prije svake primjene Removaba mora se drenirati ascites do prestanka spontanog istjecanja ili do smirivanja simptoma (vidjeti dio 4.4).
English: Your doctor may consider reducing the infusion rate of Removab or giving you additional treatment to reduce these symptoms.
Croatian: Vaš liječnik će razmotriti smanjenje brzine infuzije Removaba ili će Vam dati potporno liječenje kako bi umanjio simptome.
English: The geometric mean apparent terminal plasma elimination half-life (t1/2) was approximately 2.5 days (range 0.7 to 17).
Croatian: Geometrijska srednja vrijednost prividnog poluvijeka eliminacije iz plazme - (t1/2) bila je približno 2,5 dana (raspon 0,7 do 17).
English: Hepatic enzymes
Croatian: Jetreni enzimi
English: Performance status and BMI
Croatian: Funkcionalno stanje i ITM
English: • The peelable sticker, which is provided on the inner side of the Removab carton box, displaying the text “Diluted Removab.
Croatian: • Naljepnica koja se može odvojiti s unutrašnje strane Removab kartonske kutije, a na kojoj je natpis "Razrijeđeni Removab.
English: Catumaxomab was detectable in the ascites fluid and in plasma.
Croatian: Katumaksomab je bio detektibilan u ascitesu i u plazmi.
English: Cholangitis*, hyperbilirubinaemia.
Croatian: Kolangitis*, hiperbilirubinemija
English: Despite pre-existing ADA values all patients received all 4 catumaxomab infusions.
Croatian: Unatoč preterapijskim vrijednostima adenozin deaminaze svi su bolesnici primili sve 4 infuzije katumaksomaba.
English: What you need to know before you use Removab
Croatian: Što morate znati prije nego počnete primjenjivati Removab
English: 728 patients received catumaxomab intraperitoneally, 293 patients as 6 hour - and 435 patients as 3 hour infusions.
Croatian: bolesnika primilo je katumaksomab intraperitonealno, 293 bolesnika u obliku infuzije u trajanju od 6 sati i 435 bolesnika u obliku infuzije u trajanju od 3 sata.
English: In order to assess the impact of prednisolone premedication on safety and efficacy the primary safety endpoint “composite safety score” and the co-primary efficacy endpoint “puncture-free survival” were investigated.
Croatian: Kako bi se procijenio učinak premedikacije prednizolonom na sigurnost i djelotvornost, kao primarni ishod sigurnosti ispitivan je "kompozitni sigurnosni rezultat", a kao dodatni primarni ishod djelotvornosti "preživljenje bez punkcije".
English: Before you start using Removab your doctor will check your: - Body Mass Index (BMI), which depends on your height and weight - Karnofsky Index, a measure of your general performance status.
Croatian: Prije nego započnete s primjenom Removaba, liječnik će provjeriti Vaš: - Indeks tjelesne mase (ITM), koji ovisi o Vašoj visini i težini
English: Patients receiving a higher than recommended dose of catumaxomab experienced more severe (grade 3) adverse reactions.
Croatian: Bolesnici koji su primali doze katumaksomaba veće od preporučenih imali su ozbiljnije (stupanj 3) nuspojave.
English: Decreased appetite* / anorexia, dehydration*, hypokalaemia, hypoalbuminaemia, hyponatraemia*, hypocalcaemia*, hypoproteinaemia.
Croatian: Smanjen apetit*/anoreksija, dehidracija*, hipokalijemija, hipoalbuminemija, hiponatrijemija*, hipokalcijemija*, hipoproteinemija
English: The infusion must be administered at constant rate with duration time of at least 3 hours.
Croatian: Infuzija se mora primjenjivati konstantnom brzinom tijekom najmanje 3 sata.
English: Removab is indicated for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
Croatian: Removab je indiciran za liječenje malignog ascitesa intraperitonealnom primjenom u odraslih s EpCAM pozitivnim karcinomima u kojih standardno liječenje nije dostupno ili više nije indicirano.
English: In the clinical studies in patients with malignant ascites, 1,000 mg paracetamol intravenously was routinely administered prior to Removab infusion for pain and pyrexia control.
Croatian: U kliničkim ispitivanjima u bolesnika s malignim ascitesom rutinski je intravenski primjenjivano 1000 mg paracetamola prije infuzije Removaba sa svrhom kontrole boli i pireksije.
English: Infusion-related side effects and abdominal pain are very common (see section 4).
Croatian: Nuspojave vezane uz infuziju i bol u trbuhu vrlo su česti (pogledajte dio 4).
English: Catumaxomab is a trifunctional rat-mouse hybrid monoclonal antibody that is specifically directed against the epithelial cell adhesion molecule (EpCAM) and the CD3 antigen.
Croatian: Katumaksomab je trifunkcionalno monoklonalno hibridno štakorsko-mišje protutijelo koje je specifično usmjereno protiv adhezijskih molekula epitelnih stanica (EpCAM) i CD3 antigena.
English: OTHER Neovii Biotech GmbH
Croatian: Neovii Biotech GmbH
English: Fertility No data on the effect of catumaxomab on fertility are available.
Croatian: Nisu dostupni podaci o učinku katumaksomaba na plodnost.
English: The prepared infusion solution should be used immediately.
Croatian: Pripremljenu otopinu za infuziju potrebno je odmah primijeniti.
English: The anti-tumour activity of catumaxomab has been demonstrated in vitro and in vivo.
Croatian: Antitumorska aktivnost katumaksomaba dokazana je in vitro i in vivo.
English: The geometric mean plasma Cmax was approximately 0.5 ng/ml (range 0 to 2.3), and the geometric mean plasma AUC was approximately 1.7 day* ng/ml (range < LLOQ (lower limit of quantification) to 13.5).
Croatian: Geometrijska srednja vrijednost plazmatske Cmax bila je približno 0,5 ng/ml (raspon od 0 do 2,3), a geometrijska srednja vrijednost plazmatskog AUC-a bila je približno 1,7 dan* ng/ml (raspon < od donje granice mjerljivosti do 13,5).
English: As secondary efficacy endpoint overall survival (Table 6) was assessed.
Croatian: Kao sekundarni ishod procjenjivano je ukupno preživljenje (Tablica 6)
English: Very common serious side effects (may affect more than 1 in 10 people): - Tiredness
Croatian: Vrlo česte ozbiljne nuspojave (mogu se javiti u više od 1 na 10 osoba): - Umor
English: Removab must be administered as an intraperitoneal infusion only.
Croatian: Removab se mora primjenjivati isključivo u obliku intraperitonealne infuzije.
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati Removab Ovaj lijek čuvajte izvan pogleda i dohvata djece.
English: Systemic Inflammatory Response Syndrome (SIRS), which may also occur commonly due to the mechanism of action of catumaxomab, develops, in general, within 24 hours after Removab infusion, showing symptoms of fever, tachycardia, tachypnoea and leucocytosis (see section 4.8).
Croatian: Sindrom sistemskog upalnog odgovora, koji se također može pojaviti zbog mehanizma djelovanja katumaksomaba, općenito se razvija unutar 24 sata nakon infuzije Removaba sa simptomima vrućice, tahikardije, tahipneje i leukocitoze (vidjeti dio 4.8).
English: Removab is used to treat malignant ascites, when standard treatment is not available or no longer feasible.
Croatian: Removab se koristi za liječenje zloćudnog ascitesa kada standardno liječenje nije dostupno ili se više u bolesnika ne može primijeniti.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 April 2009
Croatian: DATUM PRVOG ODOBRENJA/DATUM OBNOVE ODOBRENJA
English: Figure 2 Illustration of the transfer of Removab from the pre-filled syringe to the 50 ml syringe
Croatian: Slika 2 Ilustracija prijenosa Removaba iz napunjene štrcaljke u štrcaljku od 50 ml
English: A perfusion tubing of an inner diameter of 1 mm and a length of 150 cm must be used.
Croatian: Moraju se koristiti perfuzijske cijevi s unutrašnjim promjerom od 1 mm i dužinom od 150 cm.
English: Paracentesis + catumaxomab (N=170)
Croatian: Paracenteza + katumaksomab (N=170)
English: There are no or limited amount of data from the use of catumaxomab in pregnant women.
Croatian: Nema podataka ili su podaci o primjeni katumaksomaba u trudnica ograničeni.
English: In this study, the primary efficacy endpoint was puncture-free survival, which was a composite endpoint defined as the time to first need for therapeutic ascites puncture or death, whichever occurred first.
Croatian: U ovom ispitivanju primarni ishod djelotvornosti bilo je preživljenje bez punkcije što predstavlja kompozitni ishod definiran kao vrijeme do prve potrebne terapijske punkcije ascitesa ili smrti, što god se prije dogodilo.
English: The safety profile of catumaxomab using a 3h versus a 6h infusion time is in general comparable in regards to nature, frequency and severity.
Croatian: Sigurnosni profil katumaksomaba pri trosatnoj u odnosu na infuziju od 6 sati usporediv je s obzirom na vrstu, učestalost i težinu nuspojava.
English: The following definitions of CTCAE criteria of the US National Cancer Institute (version 4.0) apply: CTCAE grade 1 = mild, CTCAE grade 2 = moderate, CTCAE grade 3 = severe, CTCAE grade 4 = life-threatening
Croatian: (verziji 4.0): CTCAE stupanj 1 = blage, CTCAE stupanj 2 = umjerene, CTCAE stupanj 3 = teške, CTCAE
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/512/002
Croatian: EU/1/09/512/002
English: • polyethylene perfusion tubings with an inner diameter of 1 mm and a length of 150 cm
Croatian: • polietilenskim perfuzijskim cijevima s unutrašnjim promjerom od 1 mm i dužinom od 150 cm
English: Other or additional standard pre-medication with analgesic / antipyretic / nonsteroidal antiphlogistic medicinal products is recommended.
Croatian: Preporučuje se druga ili dodatna standardna premedikacija s analgetičkim/antipiretičkim/nesteroidnim antiflogističnim lijekovima.
English: All patients experienced symptoms related to catumaxomab mode of action with a safety profile comparable in nature to the first i.p.
Croatian: Svi su bolesnici imali simptome vezane uz mehanizam djelovanja katumaksomaba sa sigurnosnim profilom usporedivim u s onim pri prvom ciklusu liječenja i.p. infuzijama.
English: Removab contains the active substance catumaxomab, a monoclonal antibody.
Croatian: Removab sadrži djelatnu tvar katumaksomab, monoklonsko protutijelo.
English: How to store Removab
Croatian: Kako primjenjivati Removab
English: The efficacy of the treatment with paracentesis and catumaxomab in patients with malignant ascites due to EpCAM-positive carcinomas was statistically significantly superior to that with paracentesis alone in terms of puncture-free survival and time to first need for therapeutic ascites puncture.
Croatian: Djelotvornost liječenja paracentezom i katumaksomabom u bolesnika sa zloćudnim ascitesom zbog EpCAM pozitivnih karcinoma bila je statistički značajno veća od one sa samom paracentezom u odnosu na preživljenje bez punkcije i vrijeme do prve potrebne terapijske punkcije ascitesa.
English: The most common infusion-related side effects, which are mostly mild to moderate, are fever, chills, feeling sick and vomiting.
Croatian: Najčešće nuspojave vezane uz infuziju, koje su većinom blage do umjerene, su vrućica, zimica, mučnina i povraćanje.